Statins in the management of dyslipidemia associated with chronic kidney disease (Q37986355)

26 August 2017

Statins in the management of dyslipidemia associated with chronic kidney disease (English)

1 reference

26 August 2017

1 reference

Murray Epstein

1

1 reference

26 August 2017

Nosratola D Vaziri

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

Nature Reviews Nephrology

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

214-223

1 reference

26 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2012.33

26 August 2017

0 references

cites work

The incidence of end-stage renal disease in India: a population-based study.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Early detection and prevention of diabetic nephropathy: a challenge calling for mandatory action for Mexico and the developing world.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Preventive strategies of renal failure in the Arab world

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Excerpts from the United States Renal Data System 2007 annual data report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Risk Factors for Coronary Artery Disease in Patients with Renal Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Chronic kidney disease and mortality risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Atherosclerosis in CKD: differences from the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Novel cardiovascular risk factors in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Statins, inflammation and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Rosuvastatin in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Dialysis modalities and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipoprotein metabolism and lipid management in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

New insights into lipid metabolism in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Effect of pravastatin in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

HDL metabolism and activity in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

HDL-inflammatory index correlates with poor outcome in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

LRP: a multifunctional scavenger and signaling receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Down-regulation of VLDL receptor expression in chronic experimental renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Reverse cholesterol transport pathway in experimental chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Adverse effects of statins - mechanisms and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipid metabolism in dialysis patients-the story gets more complicated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Cardiovascular risk and management in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Inflammation in end-stage renal disease: sources, consequences, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Oxidative stress in uremia: nature, mechanisms, and potential consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipid disorders and their relevance to outcomes in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Chronic renal diseases as a public health problem: epidemiology, social, and economic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

SHARP: a stab in the right direction in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Diabetic kidney disease: act now or pay later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Projecting the number of patients with end-stage renal disease in the United States to the year 2015

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Outcome and risk factors of ischemic heart disease in chronic uremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Sunset for statins after AURORA?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Hyperlipidemia in patients with chronic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition Examination Survey (1991-1994)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Down-regulation of hepatic lipase expression in experimental nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

New insights into lipid metabolism in the nephrotic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.33

Cardiovascular disease and chronic renal disease: a new paradigm.

31 March 2020

1 reference

12 December 2020

Clinical epidemiology of cardiovascular disease in chronic renal disease

1 reference

12 December 2020

Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line.

1 reference

12 December 2020

Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients

1 reference

12 December 2020

Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure

1 reference

12 December 2020

K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.33

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference